Dominic Borie
Hoofd Techniek/Wetenschap/O&O bij KYVERNA THERAPEUTICS, INC.
Vermogen: 7 M $ op 30-04-2024
Actieve functies van Dominic Borie
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| KYVERNA THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 13-10-2022 | - |
| Directeur/Bestuurslid | 01-01-2020 | 13-10-2022 | |
| Algemeen Directeur | 01-01-2020 | 13-10-2022 | |
| President | 01-01-2020 | 13-10-2022 |
Loopbaan van Dominic Borie
Eerdere bekende functies van Dominic Borie
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| Stanford University | Corporate Officer/Principal | - | - |
| AMGEN INC. | Hoofd Techniek/Wetenschap/O&O | - | - |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - | - |
| ALLOGENE THERAPEUTICS, INC. | Directeur/Bestuurslid | - | - |
Opleiding van Dominic Borie
| The University of Texas at Austin | Doctorate Degree |
| North Carolina State University | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 8 |
| Ierland | 2 |
Operationeel
| Corporate Officer/Principal | 3 |
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
Sectoraal
| Health Technology | 6 |
| Consumer Services | 4 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| KYVERNA THERAPEUTICS, INC. | Health Technology |
| ALLOGENE THERAPEUTICS, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
- Beurs
- Insiders
- Dominic Borie
- Ervaring
